Biotech Values

[genisi]

To date no two DAA (no ifn) has shown good efficacy in G1a patients (G1b is, apparently, a different matter - see #msg-67597202). So why would one DAA + rib (a relatively weak drug) be expected to be a cure?

I don't think expectations were for a cure a la GT2/3 but for a decent SVR and therefore the results were disappointing.
Few reasons I can think of for expectations are: first it's a nuke containing regimen and 7977 is a potent nuke in all HCV genotypes. Also, all 10 nulls achieved RVR. Another possible point is that in PROTON trial all 13 GT1 patients with genotype TT in IL28B (IFN poor responders), achieved RVR and SVR12.